Molecular Diagnosis of Chronic Liver Disease and Hepatocellular Carcinoma: The Potential of Gene Expression Profiling

Eric R. Lemmer; Scott L. Friedman; Josep M. Llovet

doi:10.1055/s-2006-951604

Seminars in Liver Disease, Inhaltsverzeichnis

Semin Liver Dis 2006; 26(4): 373-384
DOI: 10.1055/s-2006-951604

Molecular Diagnosis of Chronic Liver Disease and Hepatocellular Carcinoma: The Potential of Gene Expression Profiling

Eric R. Lemmer¹ , Scott L. Friedman¹ , Josep M. Llovet¹ ^, ²

¹Mount Sinai Liver Cancer Program, Division of Liver Disease, Department of Medicine, Mount Sinai School of Medicine, New York, New York
²Barcelona-Clínic Liver Cancer (BCLC) Group, IDIBAPS, Liver Unit, Hospital Clínic, Barcelona, Spain

Abstract

ABSTRACT

Gene expression profile analysis through DNA microarrays and other high-throughput technologies permit simultaneous investigation of all genes within a biologic sample, providing a snapshot of the transcriptional state of healthy or diseased tissue. Although most of the current applications are still geared toward research (study of disease mechanisms/signaling pathways involved, identification of novel oncogenes/tumor suppressor genes), clinical diagnostic applications of this approach are beginning to enter more routine molecular usage. There are clear examples where a group of genes, or “signature,” can provide clinically useful information (e.g., cancer prognosis and response to treatment). Importantly, the identification of genes that are up-regulated during tumorigenesis is heralding a new era of targeted molecular therapies in oncology. In addition, the high capacity of the technologies available allow for the identification of new biomarkers for early diagnosis. In the future, gene expression profiling (“disease fingerprinting”) is likely to complement liver biopsy in the molecular differential diagnosis of chronic liver diseases and hepatocellular carcinoma (HCC). There has already been some success in the identification of subtypes of HCC based on derived sets of signature gene clusters. Data recently reported have been able to provide the first molecular classification of HCC, although more comprehensive studies are required to confirm these results and translate them into the clinical practice. In fact, variations in gene expression in normal and diseased livers, as well technical factors, are obstacles to the routine use of microarray-based methods in the liver clinic. Continued progress is anticipated in the practical application of gene array methods to refine diagnosis and therapy of HCC.

KEYWORDS

Gene expression profiles - transcriptome - microarrays - integrative genomic analysis - biomarkers - liver diseases - hepatocellular carcinoma

Volltext

Referenzen

REFERENCES

1 Venter J C, Adams M D, Myers E W et al.. The sequence of the human genome. Science. 2001; 291 1304-1351
2 Guttmacher A E, Collins F S. Genomic medicine: a primer. N Engl J Med. 2002; 347 1512-1520
3 Bucca G, Carruba G, Saetta A, Muti P, Castagnetta L, Smith C P. Gene expression profiling of human cancers. Ann NY Acad Sci. 2004; 1028 28-37
4 Csako G. Present and future of rapid and/or high-throughput methods for nucleic acid testing. Clin Chim Acta. 2006; 363 6-31
5 Thorgeirsson S S, Lee J S, Grisham J W. Molecular prognostication of liver cancer: end of the beginning. J Hepatol. 2006; 44 798-805
6 Thorgeirsson S S, Lee J S, Grisham J W. Functional genomics of hepatocellular carcinoma. Hepatology. 2006; 43(suppl 1) S145-S150
7 Shackel N A, Gorrell M D, McCaughan G W. Gene array analysis and the liver. Hepatology. 2002; 36 1313-1325
8 Michiels S, Koscielny S, Hill C. Prediction of cancer outcome with microarrays: a multiple random validation strategy. Lancet. 2005; 365 488-492
9 Kurian K M, Watson C J, Wyllie A H. DNA chip technology. J Pathol. 1999; 187 267-271
10 Gerhold D, Rushmore T, Caskey C T. DNA chips: promising toys have become powerful tools. Trends Biochem Sci. 1999; 24 168-173
11 Heller M J. DNA microarray technology: devices, systems, and applications. Annu Rev Biomed Eng. 2002; 4 129-153
12 Gingeras T R, Higuchi R, Kricka L J, Lo Y M, Wittwer C T. Fifty years of molecular (DNA/RNA) diagnostics. Clin Chem. 2005; 51 661-671
13 Stears R L, Martinsky T, Schena M. Trends in microarray analysis. Nat Med. 2003; 9 140-145
14 Miller L D, Long P M, Wong L, Mukherjee S, McShane L M, Liu E T. Optimal gene expression analysis by microarrays. Cancer Cell. 2002; 2 353-361
15 Russo G, Zegar C, Giordano A. Advantages and limitations of microarray technology in human cancer. Oncogene. 2003; 22 6497-6507
16 Simon R. Diagnostic and prognostic prediction using gene expression profiles in high-dimensional microarray data. Br J Cancer. 2003; 89 1599-1604
17 Espinosa E, Redondo A, Vara J A et al.. High-throughput techniques in breast cancer: a clinical perspective. Eur J Cancer. 2006; 42 598-607
18 Barrett J C, Kawasaki E S. Microarrays: the use of oligonucleotides and cDNA for the analysis of gene expression. Drug Discov Today. 2003; 8 134-141
19 Baranova A, Schlauch K, Gowder S, Collantes R, Chandhoke V, Younossi Z M. Microarray technology in the study of obesity and non-alcoholic fatty liver disease. Liver Int. 2005; 25 1091-1096
20 Brazma A, Hingamp P, Quackenbush J et al.. Minimum information about a microarray experiment (MIAME): toward standards for microarray data. Nat Genet. 2001; 29 365-371
21 International Human Genome Sequencing Consortium . Finishing the euchromatic sequence of the human genome. Nature. 2004; 431 931-945
22 Greenbaum D, Baruch A, Hayrapetian L et al.. Chemical approaches for functionally probing the proteome. Mol Cell Proteomics. 2002; 1 60-68
23 Velculescu V E, Madden S L, Zhang L et al.. Analysis of human transcriptomes. Nat Genet. 1999; 23 387-388
24 Kmiec Z. Cooperation of liver cells in health and disease. Adv Anat Embryol Cell Biol. 2001; 161 III-XIII, 1-151
25 Soukas A, Socci N D, Saatkamp B D, Novelli S, Friedman J M. Distinct transcriptional profiles of adipogenesis in vivo and in vitro. J Biol Chem. 2001; 276 34167-34174
26 Morley M, Molony C M, Weber T M et al.. Genetic analysis of genome-wide variation in human gene expression. Nature. 2004; 430 743-747
27 Yano N, Habib N A, Fadden K J et al.. Profiling the adult human liver transcriptome: analysis by cDNA array hybridization. J Hepatol. 2001; 35 178-186
28 Wong L Y, Hafeman A, Boyd V L et al.. Assessing gene expression variation in normal human tissues using GeneTag, a novel, global, sensitive profiling method. J Biotechnol. 2003; 101 199-217
29 Honda M, Kaneko S, Kawai H, Shirota Y, Kobayashi K. Differential gene expression between chronic hepatitis B and C hepatic lesion. Gastroenterology. 2001; 120 955-966
30 Shackel N A, McGuinness P H, Abbott C A, Gorrell M D, McCaughan G W. Insights into the pathobiology of hepatitis C virus-associated cirrhosis: analysis of intrahepatic differential gene expression. Am J Pathol. 2002; 160 641-654
31 Smith M W, Yue Z N, Korth M J et al.. Hepatitis C virus and liver disease: global transcriptional profiling and identification of potential markers. Hepatology. 2003; 38 1458-1467
32 Su A I, Pezacki J P, Wodicka L et al.. Genomic analysis of the host response to hepatitis C virus infection. Proc Natl Acad Sci U S A. 2002; 99 15669-15674
33 Bigger C B, Guerra B, Brasky K M et al.. Intrahepatic gene expression during chronic hepatitis C virus infection in chimpanzees. J Virol. 2004; 78 13779-13792
34 Sreekumar R, Rosado B, Rasmussen D, Charlton M. Hepatic gene expression in histologically progressive nonalcoholic steatohepatitis. Hepatology. 2003; 38 244-251
35 Younossi Z M, Gorreta F, Ong J P et al.. Hepatic gene expression in patients with obesity-related non-alcoholic steatohepatitis. Liver Int. 2005; 25 760-771
36 Younossi Z M, Baranova A, Ziegler K et al.. A genomic and proteomic study of the spectrum of nonalcoholic fatty liver disease. Hepatology. 2005; 42 665-674
37 Yamashita T, Hashimoto S, Kaneko S et al.. Comprehensive gene expression profile of a normal human liver. Biochem Biophys Res Commun. 2000; 269 110-116
38 Bigger C B, Brasky K M, Lanford R E. DNA microarray analysis of chimpanzee liver during acute resolving hepatitis C virus infection. J Virol. 2001; 75 7059-7066
39 Wieland S F, Chisari F V. Stealth and cunning: hepatitis B and hepatitis C viruses. J Virol. 2005; 79 9369-9380
40 Chen L, Borozan I, Feld J et al.. Hepatic gene expression discriminates responders and nonresponders in treatment of chronic hepatitis C viral infection. Gastroenterology. 2005; 128 1437-1444
41 McCaughan G W, Zekry A. Pathogenesis of hepatitis C virus recurrence in the liver allograft. Liver Transpl. 2002; 8(suppl 1) S7-S13
42 Mansfield E S, Sarwal M M. Arraying the orchestration of allograft pathology. Am J Transplant. 2004; 4 853-862
43 Wieland S, Thimme R, Purcell R H, Chisari F V. Genomic analysis of the host response to hepatitis B virus infection. Proc Natl Acad Sci U S A. 2004; 101 6669-6674
44 Seth D, Leo M A, McGuinness P H et al.. Gene expression profiling of alcoholic liver disease in the baboon (Papio hamadryas) and human liver. Am J Pathol. 2003; 163 2303-2317
45 Shackel N A, McGuinness P H, Abbott C A, Gorrell M D, McCaughan G W. Novel differential gene expression in human cirrhosis detected by suppression subtractive hybridization. Hepatology. 2003; 38 577-588
46 Shackel N A, McGuinness P H, Abbott C A, Gorrell M D, McCaughan G W. Identification of novel molecules and pathogenic pathways in primary biliary cirrhosis: cDNA array analysis of intrahepatic differential gene expression. Gut. 2001; 49 565-576
47 Parkin D M, Bray F, Ferlay J, Pisani P. Estimating the world cancer burden: Globocan 2000. Int J Cancer. 2001; 94 153-156
48 El-Serag H B, Mason A C. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med. 1999; 340 745-750
49 Tanaka Y, Hanada K, Mizokami M et al.. Inaugural article: a comparison of the molecular clock of hepatitis C virus in the United States and Japan predicts that hepatocellular carcinoma incidence in the United States will increase over the next two decades. Proc Natl Acad Sci U S A. 2002; 99 15584-15589
50 Llovet J M, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet. 2003; 362 1907-1917
51 Mazzaferro V, Regalia E, Doci R et al.. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med. 1996; 334 693-699
52 Thorgeirsson S S, Grisham J W. Molecular pathogenesis of human hepatocellular carcinoma. Nat Genet. 2002; 31 339-346
53 Bruix J, Boix L, Sala M, Llovet J M. Focus on hepatocellular carcinoma. Cancer Cell. 2004; 5 215-219
54 De Souza A T, Hankins G R, Washington M K, Orton T C, Jirtle R L. M6P/IGF2R gene is mutated in human hepatocellular carcinomas with loss of heterozygosity. Nat Genet. 1995; 11 447-449
55 Roberts L R, Gores G J. Hepatocellular carcinoma: molecular pathways and new therapeutic targets. Semin Liver Dis. 2005; 25 212-225
56 Laurent-Puig P, Legoix P, Bluteau O et al.. Genetic alterations associated with hepatocellular carcinomas define distinct pathways of hepatocarcinogenesis. Gastroenterology. 2001; 120 1763-1773
57 Schwartz J, Llovet J M. Molecular biology and targeting in hepatocellular carcinoma. In: Wadler S, Antman K, Kaufman H Molecular Targeting in Oncology. Totowa, NJ; Humana Press 2006 In press
58 Ye Q H, Qin L X, Forgues M et al.. Predicting hepatitis B virus-positive metastatic hepatocellular carcinomas using gene expression profiling and supervised machine learning. Nat Med. 2003; 9 416-423
59 Moinzadeh P, Breuhahn K, Stutzer H, Schirmacher P. Chromosome alterations in human hepatocellular carcinomas correlate with aetiology and histological grade: results of an explorative CGH meta-analysis. Br J Cancer. 2005; 92 935-941
60 Zhao X, Weir B A, LaFramboise T et al.. Homozygous deletions and chromosome amplifications in human lung carcinomas revealed by single nucleotide polymorphism array analysis. Cancer Res. 2005; 65 5561-5570
61 Llovet J M, Bru C, Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis. 1999; 19 329-338
62 Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology. 2005; 42 1208-1236
63 Bruix J, Sherman M, Llovet J M et al.. Clinical management of hepatocellular carcinoma: conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol. 2001; 35 421-430
64 Okabe H, Satoh S, Kato T et al.. Genome-wide analysis of gene expression in human hepatocellular carcinomas using cDNA microarray: identification of genes involved in viral carcinogenesis and tumor progression. Cancer Res. 2001; 61 2129-2137
65 Iizuka N, Oka M, Yamada-Okabe H et al.. Comparison of gene expression profiles between hepatitis B virus- and hepatitis C virus-infected hepatocellular carcinoma by oligonucleotide microarray data on the basis of a supervised learning method. Cancer Res. 2002; 62 3939-3944
66 Nam S W, Park J Y, Ramasamy A et al.. Molecular changes from dysplastic nodule to hepatocellular carcinoma through gene expression profiling. Hepatology. 2005; 42 809-818
67 Smith M W, Yue Z N, Geiss G K et al.. Identification of novel tumor markers in hepatitis C virus-associated hepatocellular carcinoma. Cancer Res. 2003; 63 859-864
68 Iizuka N, Oka M, Yamada-Okabe H et al.. Oligonucleotide microarray for prediction of early intrahepatic recurrence of hepatocellular carcinoma after curative resection. Lancet. 2003; 361 923-929
69 Kurokawa Y, Matoba R, Takemasa I et al.. Molecular-based prediction of early recurrence in hepatocellular carcinoma. J Hepatol. 2004; 41 284-291
70 Lee J S, Chu I S, Heo J et al.. Classification and prediction of survival in hepatocellular carcinoma by gene expression profiling. Hepatology. 2004; 40 667-676
71 Lee J S, Heo J, Libbrecht L et al.. A novel prognostic subtype of human hepatocellular carcinoma derived from hepatic progenitor cells. Nat Med. 2006; 12 410-416
72 Llovet J M, Schwartz M, Mazzaferro V. Resection and liver transplantation for hepatocellular carcinoma. Semin Liver Dis. 2005; 25 181-200
73 Bolondi L, Gaiani S, Celli N et al.. Characterization of small nodules in cirrhosis by assessment of vascularity: the problem of hypovascular hepatocellular carcinoma. Hepatology. 2005; 42 27-34
74 Kojiro M, Roskams T. Early hepatocellular carcinoma and dysplastic nodules. Semin Liver Dis. 2005; 25 133-142
75 Lencioni R, Cioni D, Crocetti L, Della Pina C, Bartolozzi C. Magnetic resonance imaging of liver tumors. J Hepatol. 2004; 40 162-171
76 Marrero J A, Lok A S. Newer markers for hepatocellular carcinoma. Gastroenterology. 2004; 127(suppl 1) S113-S119
77 Chuma M, Sakamoto M, Yamazaki K et al.. Expression profiling in multistage hepatocarcinogenesis: identification of HSP70 as a molecular marker of early hepatocellular carcinoma. Hepatology. 2003; 37 198-207
78 Paradis V, Bieche I, Dargere D et al.. Molecular profiling of hepatocellular carcinomas (HCC) using a large-scale real-time RT-PCR approach: determination of a molecular diagnostic index. Am J Pathol. 2003; 163 733-741
79 Paradis V, Degos F, Dargere D et al.. Identification of a new marker of hepatocellular carcinoma by serum protein profiling of patients with chronic liver diseases. Hepatology. 2005; 41 40-47
80 Terasaki S, Kaneko S, Kobayashi K, Nonomura A, Nakanuma Y. Histological features predicting malignant transformation of nonmalignant hepatocellular nodules: a prospective study. Gastroenterology. 1998; 115 1216-1222
81 Borzio M, Fargion S, Borzio F et al.. Impact of large regenerative, low grade and high grade dysplastic nodules in hepatocellular carcinoma development. J Hepatol. 2003; 39 208-214
82 Seki S, Sakaguchi H, Kitada T et al.. Outcomes of dysplastic nodules in human cirrhotic liver: a clinicopathological study. Clin Cancer Res. 2000; 6 3469-3473
83 Strausberg R L, Simpson A J, Old L J, Riggins G J. Oncogenomics and the development of new cancer therapies. Nature. 2004; 429 469-474
84 Hynes N E, Lane H A. ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer. 2005; 5 341-354
85 Capdeville R, Buchdunger E, Zimmermann J, Matter A. Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug. Nat Rev Drug Discov. 2002; 1 493-502
86 Johnson J R, Cohen M, Sridhara R et al.. Approval summary for erlotinib for treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of at least one prior chemotherapy regimen. Clin Cancer Res. 2005; 11 6414-6421
87 Ferrara N, Hillan K J, Gerber H P, Novotny W. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov. 2004; 3 391-400
88 Thomas M B, Abbruzzese J L. Opportunities for targeted therapies in hepatocellular carcinoma. J Clin Oncol. 2005; 23 8093-8108
89 Eckel F, von Delius S, Mayr M et al.. Pharmacokinetic and clinical phase II trial of imatinib in patients with impaired liver function and advanced hepatocellular carcinoma. Oncology. 2005; 69 363-371
90 Philip P A, Mahoney M R, Allmer C et al.. Phase II study of Erlotinib (OSI-774) in patients with advanced hepatocellular cancer. J Clin Oncol. 2005; 23 6657-6663
91 Zhu A X, Blaszkowsky L S, Ryan D P et al.. Phase II study of gemcitabine and oxaliplatin in combination with bevacizumab in patients with advanced hepatocellular carcinoma. J Clin Oncol. 2006; 24 1898-1903
92 Sachidanandam R, Weissman D, Schmidt S C et al.. A map of human genome sequence variation containing 1.42 million single nucleotide polymorphisms. Nature. 2001; 409 928-933
93 Cutler D J, Zwick M E, Carrasquillo M M et al.. High-throughput variation detection and genotyping using microarrays. Genome Res. 2001; 11 1913-1925
94 Garraway L A, Widlund H R, Rubin M A et al.. Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma. Nature. 2005; 436 117-122
95 Zhao X, Li C, Paez J G et al.. An integrated view of copy number and allelic alterations in the cancer genome using single nucleotide polymorphism arrays. Cancer Res. 2004; 64 3060-3071
96 Rhodes D R, Chinnaiyan A M. Integrative analysis of the cancer transcriptome. Nat Genet. 2005; 37(suppl) S31-S37
97 Hood L, Heath J R, Phelps M E, Lin B. Systems biology and new technologies enable predictive and preventative medicine. Science. 2004; 306 640-643

Josep M LlovetM.D.

Division of Liver Diseases, Mount Sinai School of Medicine

1425 Madison Avenue, 11F-70, Box 1123, New York, NY 10029